Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. - Wikidata - awgldk - TriplyDB

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

http://www.wikidata.org/entity/Q37948748

about

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis When to treat patients with relapsed follicular lymphoma.Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03 Targeting CD20 in melanoma patients at high risk of disease recurrence.Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma.Follicular lymphoma - treatment and prognostic factors.Pathogenesis of follicular lymphoma Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?Long-term outcomes of high dose treatment and autologous stem cell transplantation in follicular and mantle cell lymphomas - a single centre experience.Rituximab maintenance versus retreatment in follicular lymphoma.Current and future management of follicular lymphoma.Cost-effectiveness of rituximab in follicular lymphoma.Kinase dysfunction and kinase inhibitors.Rituximab therapy in nephrotic syndrome: implications for patients' management.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.Rituximab biosimilars.Treatment approaches to asymptomatic follicular lymphoma.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.Bendamustine associated immune suppression and infections during therapy of hematological malignancies.Follicular lymphoma: an Institutional Analysis A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma.Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.Rituximab for the treatment of follicular lymphoma.Herpetic tracheitis in association with rituximab therapy.Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.Multiparameter Flow Cytometry to Detect Hematogones and to Assess B-lymphocyte clonality in Bone Marrow Samples from Patients with Non-Hodgkin Lymphomas.Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.Recurrent Bordetella holmesii bacteremia and nasal carriage in a patient receiving rituximab.Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.Maintenance rituximab revisited: is it worth the cost?

P2860

Q26775837-28E68DBF-3F8E-4B0A-AA4E-33D5B34B1732 Q27011282-39BACB52-39BC-4C3F-9A34-2831BFEF1700 Q27025272-229F03F5-8D8F-4444-B7D4-B55D5A329E4E Q30238528-1142022D-46D8-4F65-8736-6EEA9DEF88DB Q33406742-B681194C-11DF-4D85-870D-DFE3772C0AD9 Q34646321-072E58D2-6D35-41B5-8917-42056BAAFA4D Q35880154-0954276F-2C5A-4989-BD41-26EB6D35DA7E Q35939451-47F2357B-C702-4003-A99B-208CB7D95FD2 Q36076716-20179CCC-E138-4B5F-AE19-3820FD79E18A Q36214120-FE8FC3F6-1DC0-45AF-B14A-E4FD027CA188 Q36283823-8E5890E1-7594-4190-ADDE-5B7A0549B724 Q36290288-6FD552A5-205B-41E2-9C1A-05C901A9E348 Q36305803-EE894593-9C05-492F-A69C-E0A96A5E1EE0 Q37671462-3447535B-012F-4826-9018-EF7B6C561619 Q38050339-2405527D-8C20-498E-8770-5F3FC706832A Q38056393-E398F4CE-40E4-4BD3-972F-3FF6193B4F43 Q38058840-998FAAEB-A533-4650-9FFC-3C43CBD55732 Q38075152-3B580374-E546-449F-9B2C-2DEB18CC86C0 Q38075787-3243A2B6-3F40-436D-9695-D07B634CEAD0 Q38088002-2876E924-437B-4B3A-B1A8-E55CC651037D Q38094099-7D2098E9-D2C1-4408-A8CF-832448BCC6C0 Q38096425-A0F4A2D4-9663-42DE-AB43-E8118209F982 Q38100232-3952CB22-89E9-42C0-90CD-032DEB6E90BA Q38161963-7F1342BA-0DC4-45A9-BA0B-8DACA8682FEA Q38465823-D670E5C1-ABBE-4406-8E5F-17640EA24F9D Q38673151-884ABEB6-C3BB-4B69-A5B6-9DA4C539D8AB Q38676858-597D3D4D-AED5-4F75-AC2A-FD3BE600541D Q38820935-90FBAA52-D269-4D04-B3F9-F9D4631F7345 Q38992084-53FF68BF-2E02-4A61-88F5-4A5AE5D2AF4F Q39198649-B59FCCDF-1E04-49D5-8EEE-19FADB32B417 Q39215476-BD954C62-0C6B-4EDE-BC45-1701BD74964B Q39313905-053E3B70-F2B2-4AFE-9853-E0B11346C478 Q39360775-B5FA54B0-3712-4B42-962D-17481F0C0A2F Q40580285-A9721386-BEF3-4910-BA01-E08D529D226B Q41465999-6F5FE899-B9A9-43CA-B205-0601626C0966 Q42256191-BB15DCF3-7E06-4EFB-8CFD-D5483350882A Q42388537-3B568FDC-EC2F-4606-8845-2A06A2FDD270 Q42931210-926DBC44-B6C9-4A76-A76B-530688DAAEA9 Q43423234-2E261FF4-121A-47E5-BF01-80101B91D4BC Q43465410-235C9F23-C4F1-47A0-8FAC-F39A818CA025

P2860

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

http://www.wikidata.org/entity/Q37948748

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Rituximab maintenance for the ...... analysis of randomized trials.

@en

Rituximab maintenance for the ...... analysis of randomized trials.

@nl

type

label

Rituximab maintenance for the ...... analysis of randomized trials.

@en

Rituximab maintenance for the ...... analysis of randomized trials.

@nl

prefLabel

Rituximab maintenance for the ...... analysis of randomized trials.

@en

Rituximab maintenance for the ...... analysis of randomized trials.

@nl

P1433

Q37948748-FF71BCAA-2707-4442-AF93-6A51532D3CD1

P1476

Q37948748-4F7BED6E-65C2-4EC0-BDF9-D9E171BECB30

P2093

Q37948748-1E5A2BB5-B100-4869-9E4B-D5198458A2C4

Q37948748-3897FC39-1C02-4130-BE0E-0D11E28EE469

Q37948748-39A56C1B-32CC-46CE-A7FE-81157FB42F67

Q37948748-6BFFD6FF-E13E-4EFA-9C16-4CC430FA13B8

Q37948748-7D8FA290-3AC0-4678-B271-0F42154512ED

Q37948748-91FE3C89-5A4E-47F4-9EB5-4FA4BF03DC6C

Q37948748-F67D5C00-E8B8-4CB3-92B8-7F64C97B3B89

Q37948748-FA626ABF-33FE-44DE-ACBD-11C08E6AC0C2

Q37948748-FB88150A-B25A-4D34-B642-79555F1AE692

P2860

Q37948748-00C343CA-937F-4A04-9A5B-857E57734C5B

Q37948748-05E54EE6-B1FA-4547-B36E-07DE453BAD7E

Q37948748-0D2213AA-DE86-41C6-AB67-7EA81835C121

Q37948748-0EEB2111-1265-44E2-A25A-A42170ED3DBB

Q37948748-1343E6D0-2AD8-49FE-91A7-443755C32314

Q37948748-13F422C8-5211-4490-B727-E79984385716

Q37948748-1525C2EF-992C-47CB-BF3C-4BCDB972AF5D

Q37948748-1697D121-B10B-4387-9FC9-5F9D438EF53B

Q37948748-1ABF7BEB-1D8E-40E2-8CF9-7C2ED97B3561

Q37948748-1CEE4B85-7E74-4383-958C-0203BA18A94C

P304

Q37948748-3686E927-D0DE-4E16-A3C9-789E3899AE43

P31

Q37948748-5E3E86B2-57AA-4355-9BF6-5D3446B40CFD

Q37948748-b5ac504f-2d37-4148-97c1-f205cebdbe93

P356

Q37948748-55FFF13C-B483-45AA-913C-0F659AA238D3

P407

Q37948748-0214C9F2-7295-4EFB-8FEE-54297AA491D7

P433

Q37948748-C6CB9171-9AE2-4A5B-B05D-0E5A38187A20

P478

Q37948748-15001369-7F21-415B-8458-ABBEA49B0352

P577

Q37948748-133165D2-AD89-4ABB-8A56-DF4109996AF1

P5875

Q37948748-2F910A8E-2F2E-4AE5-89B1-DBB75A404372

P698

Q37948748-BFF1794F-D455-49E5-BF31-11C3BD5E00C9

P921

Q37948748-8783C100-934A-452D-AFE4-32493FDBA825

Q37948748-E4F3498E-44B4-431F-9654-B0F0804BADDA

P356

P1433

Journal of the National Cancer Institute

P1476

Rituximab maintenance for the ...... analysis of randomized trials.

@en

P2093

Anat Gafter-Gvili

http://www.w3.org/2001/XMLSchema#string

Gilles Salles

http://www.w3.org/2001/XMLSchema#string

Liat Vidal

http://www.w3.org/2001/XMLSchema#string

Martin H Dreyling

http://www.w3.org/2001/XMLSchema#string

Mathias Witzens-Harig

http://www.w3.org/2001/XMLSchema#string

Michele Ghielmini

http://www.w3.org/2001/XMLSchema#string

Ofer Shpilberg

http://www.w3.org/2001/XMLSchema#string

Ruth Pettengell

http://www.w3.org/2001/XMLSchema#string

Shu-Fang Hsu Schmitz

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Quantifying heterogeneity in a meta-analysis

Meta-analysis in clinical trials

Practical methods for incorporating summary time-to-event data into meta-analysis

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

P304

1799-1806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR418

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51737013

http://www.w3.org/2001/XMLSchema#string

P698

22021664

http://www.w3.org/2001/XMLSchema#string

P921